The State Drug Administration conditionally approved two domestic new coronavirus infection treatment drugs on the market
Read Time:41 Second
Recently, the State Drug Administration in accordance with the special drug approval procedures, emergency review and approval, conditional approval of Hainan Centrum Pharmaceutical Co., Ltd. declared a class 1 innovative drug centronavir tablets / ritonavir tablets combination package, Shanghai Wang Shi Biomedical Technology Co., Ltd. declared a class 1 innovative drug hydrobromide deuterium rimadevir tablets on the market.
Both of these drugs are oral small molecule neocoronavirus infection treatment drugs for the treatment of adult patients with mild to moderate novel coronavirus infection. Patients should use the drugs strictly according to the instructions under the guidance of a physician. The State Drug Administration requires the holder of the marketing license to continue to carry out relevant research work, the deadline for completing the requirements of the attached conditions, and timely submission of follow-up research results. (End)
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating